Отчет об анализе размера, доли и тенденций мирового рынка пемигатиниба – обзор отрасли и прогноз до 2031 года

Анализ рынка пемигатиниба

Рынок пемигатиниба значительно вырос благодаря достижениям в области точной медицины и таргетной терапии для лечения рака. Пемигатиниб, селективный ингибитор рецепторов фактора роста фибробластов (FGFR), сыграл решающую роль в лечении прогрессирующей холангиокарциномы и других видов рака, связанных с FGFR. Недавние исследования подчеркнули его эффективность в улучшении общих показателей выживаемости, что увеличило его применение в клинических условиях.

Технологические достижения, такие как служба секвенирования нового поколения (NGS), облегчили отбор пациентов для терапии пемигатинибом путем выявления генетических изменений FGFR. Этот персонализированный подход улучшает результаты лечения и способствует исследованиям комбинированной терапии, повышая эффективность и устраняя механизмы резистентности.

Рост рынка пемигатиниба также подкрепляется расширением показаний за пределы холангиокарциномы, при этом продолжаются клинические испытания, изучающие его эффективность при различных солидных опухолях. Кроме того, регулирующие разрешения во многих регионах расширили доступ к рынку. Поскольку специалисты здравоохранения продолжают отдавать приоритет таргетным методам лечения, ожидается, что спрос на пемигатиниб будет расти, подпитываемый растущим вниманием к персонализированной медицине и улучшенным стратегиям ведения пациентов. Эта тенденция указывает на надежное будущее пемигатиниба, что соответствует более широкому сдвигу в сторону таргетной терапии онкологии.

Размер рынка пемигатиниба

Объем мирового рынка пемигатиниба в 2023 году оценивался в 396,71 млн долларов США, а к 2031 году, по прогнозам, он достигнет 1336,90 млн долларов США, при среднегодовом темпе роста 16,4% в прогнозируемый период с 2024 по 2031 год. Помимо аналитических данных о рыночных сценариях, таких как рыночная стоимость, темпы роста, сегментация, географический охват и основные игроки, рыночные отчеты, подготовленные Data Bridge Market Research, также включают углубленный экспертный анализ, эпидемиологию пациентов, анализ линейки препаратов, анализ ценообразования и нормативно-правовую базу.

Тенденции рынка пемигатиниба

«Растущее внимание к точной медицине»

A significant trend in the pemigatinib market is the increasing emphasis on precision medicine, particularly in treating advanced cholangiocarcinoma. Pemigatinib, a selective inhibitor of fibroblast growth factor receptors (FGFRs), has been specifically developed for patients with FGFR2 fusions or mutations. For instance, the FDA approval of pemigatinib (brand name Pemazyre) in April 2020 marked a milestone in personalized cancer therapy, addressing an unmet need for targeted treatment options. This focus on precision medicine is driving research and development efforts, leading to combination therapies and expanded indications, thereby enhancing patient outcomes and supporting market growth in oncology therapeutics.

Report Scope and Pemigatinib Market Segmentation

Pemigatinib Market Definition

Pemigatinib is an oral medication classified as a selective inhibitor of fibroblast growth factor receptors (FGFRs). It is primarily used to treat specific types of cancer, including cholangiocarcinoma (bile duct cancer) with FGFR2 fusions or mutations. By targeting the FGFR pathway, pemigatinib helps disrupt the cancer cell growth and proliferation associated with these genetic alterations. The drug received approval from the U.S. Food and Drug Administration (FDA) in April 2020, offering a targeted treatment option for patients with advanced or metastatic disease. Ongoing research continues to evaluate its efficacy and safety in various malignancies.

Pemigatinib Market Dynamics

Drivers

• Increased Prevalence of Cancer

The rising incidence of cancer, especially cholangiocarcinoma, significantly drives the pemigatinib market. Cholangiocarcinoma, a bile duct cancer, is often associated with FGFR2 gene alterations, which pemigatinib specifically targets. For instance, according to the World Health Organization (WHO), cancer is a growing burden, and the number of new cancer cases is going to rise from 18.1 million in 2018 to 29.4 million by 2040. Therefore, the increasing prevalence of cancer is expected to boost the demand for the global oncology cancer drugs market during the forecast period. Furthermore, the rising awareness regarding cancer among the population is anticipated to favor the global market in the upcoming years.

• Growing Adoption of Companion Diagnostics

The increasing integration of companion diagnostics in oncology is a significant driver for the pemigatinib market. These diagnostics identify patients with specific genetic alterations, such as FGFR2 fusions or mutations, making them eligible for pemigatinib therapy. For instance, the FDA-approved companion diagnostic, FoundationOne CDx, aids in detecting these biomarkers, enhancing patient stratification and ensuring that the right patients receive targeted treatment. This precision approach not only improves clinical outcomes but also increases healthcare providers' confidence in prescribing pemigatinib. As more diagnostic tools become available, the market for pemigatinib is expected to expand, meeting the growing demand for personalized cancer therapies.

Opportunities

• Global Expansion of Oncology Markets

The global expansion of oncology markets, particularly in emerging economies, presents significant opportunities for pemigatinib. Countries such as India and Brazil are investing heavily in healthcare infrastructure and oncology treatments, aiming to improve patient outcomes in cancer care. For instance, India's National Cancer Control Programme is focusing on enhancing access to targeted therapies, which can include pemigatinib. In addition, the increasing prevalence of cholangiocarcinoma in these regions drives demand for effective treatment options. As healthcare systems prioritize advanced therapies, pemigatinib can establish a foothold in these markets, ultimately improving patient access to innovative cancer treatments and expanding its global footprint.

• Rising Awareness and Education

The pemigatinib market benefits significantly from rising awareness and education about rare cancers, particularly cholangiocarcinoma. Initiatives such as patient advocacy groups and educational campaigns, such as the Cholangiocarcinoma Foundation’s “Cholangiocarcinoma Awareness Month,” play a pivotal role in disseminating information. These efforts inform both healthcare providers and patients about the importance of early diagnosis and available treatments, including pemigatinib. Increased awareness encourages physicians to consider pemigatinib for eligible patients, leading to higher adoption rates. Furthermore, as patients become more knowledgeable about treatment options, they actively seek pemigatinib, creating a substantial market opportunity as the demand for targeted therapies continues to grow.

Restraints/Challenges

• Adverse Effects and Patient Compliance

Adverse effects associated with pemigatinib significantly impact patient compliance and can lead to therapy discontinuation. Common side effects include fatigue, nausea, diarrhea, and elevated liver enzymes, which may deter patients from adhering to treatment regimens. These adverse effects can lead to a reduction in quality of life and necessitate dose adjustments or interruptions in therapy. Consequently, patients may opt for alternative treatments with more manageable side effect profiles, affecting overall treatment outcomes. This lack of adherence not only compromises individual patient results but also hinders the market demand for pemigatinib, as healthcare providers may be reluctant to prescribe a therapy with challenging tolerability issues.   

• Cost and Reimbursement Issues

Cost and reimbursement issues significantly hinder the pemigatinib market. As a high-priced targeted therapy for cancers, pemigatinib presents affordability challenges for patients, leading to increased out-of-pocket expenses. These costs can deter patient adherence and overall treatment initiation. In addition, insurers often scrutinize high-cost therapies for reimbursement, creating barriers for healthcare providers to prescribe pemigatinib. In healthcare systems focused on cost containment, the reluctance of insurers to cover such expensive treatments further limits access. This financial burden not only restricts market growth but also affects treatment choices for patients, ultimately compromising the drug's potential impact in oncology.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Pemigatinib Market Scope

The market is segmented on the basis of type, application, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• 4.5 mg
• 9 mg
• 13.5mg

Application

• Cholangiocarcinoma
• Others

 Dosage

• Tablet
• Others

 Route of Administration

• Oral
• Other

 End-Users

• Clinic
• Hospital
• Others

 Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Pemigatinib Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, application, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, U.A.E, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)

North America is expected to dominate the pemigatinib market due to the presence of major key players, a well-developed healthcare sector, and advancements in treatment options. This region's robust infrastructure and increasing investment in cancer therapies further contribute to its leading position in the market.

Asia-Pacific is expected to show significant growth in the pemigatinib market during the forecast period, driven by increasing research and development activities, rising investments in the healthcare sector, and growing government support aimed at enhancing cancer treatment options and improving patient outcomes.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Pemigatinib Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Pemigatinib Market Leaders Operating in the Market Are:

• F. Hoffmann-La Roche Ltd (Switzerland)
• Genentech, Inc. (U.S.)
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• GlaxoSmithKline plc. (U.K.)
• Eli Lilly and Company (U.S.)
• AstraZeneca (U.K.)
• Sanofi (France)
• Bayer AG (Germany)

Latest Developments in Pemigatinib Market

• In June 2021, Bayer AG announced a strategic acquisition of Noria Therapeutics Inc. and PSMA Therapeutics Inc., gaining exclusive rights to the companies' investigational compound. This acquisition is expected to significantly bolster Bayer's oncology portfolio, enabling the company to enhance its research and development capabilities in cancer treatments. By integrating these innovative assets, Bayer aims to address unmet medical needs in oncology and strengthen its market position
• В апреле 2021 года компания Sanofi объявила о приобретении Tidal Therapeutics, доклинической биотехнологической компании, известной разработкой передовой исследовательской платформы на основе мРНК. Это приобретение призвано расширить исследовательские возможности Sanofi в области онкологии, иммунологии и других заболеваний. Используя технологию Tidal, Sanofi стремится ускорить разработку новых методов лечения, тем самым подкрепляя свою приверженность продвижению решений в области здравоохранения и решению различных терапевтических задач.

SKU-65965